Histology from all other organs was unremarkable. It is important that clinicians and histopathologists are aware that relapsing polychondritis can affect the respiratory tract and that this may be ...

Relapsing polychondritis Is a rare disorder that is characterised by recurrent and progressive inflammation of cartilaginous structures. Nervous system involvement in relapsing polychondritis has been ...

Objective Relapsing polychondritis (RP) is a systemic inflammatory disease of unknown aetiology. The objective of this study was to examine the contribution of rare genetic variations to RP. Methods ...

Methods In this monocentric retrospective study, SC lesions were manually delineated. Inclusion criteria were: age between 18 and 60 years, relapsing-remitting MS, disease duration under 2 years and ...

The Relapsing Multiple Sclerosis (RMS) drugs in development market research report provides comprehensive information on the therapeutics under development for Relapsing Multiple Sclerosis (RMS), ...

mayo.edu Background There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. Objective We describe our experience with ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

Ongoing Phase 3 trials are further evaluating fenebrutinib’s potential in people with relapsing and progressive forms of MS, with data from these programs expected by the end of 2025.

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...